DB05019InvestigationalProtein Based Therapies
LC16m8 is a next-generation, attenuated smallpox vaccine that is designed to have a better safety profile, yet be equally effective, compared to conventional smallpox vaccines. It is the only attenuated...
- Mechanism
- Curator reviewed
LC16m8 is produced in cell culture from vaccinia virus that has been attenuated, or modified, so that it can initiate an immune response without causing serious adverse side effects.
- Primary indication
- Investigated for use/treatment in viral infection.Curator reviewed
- Code names
- LC16M8
What you can answer from here — as of April 23, 2025
Which companies are running trials of LC16M8, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account